Clinical Trials Logo

Carcinoma, Squamous Cell clinical trials

View clinical trials related to Carcinoma, Squamous Cell.

Filter by:

NCT ID: NCT00054691 Completed - Skin Cancer Clinical Trials

ZD1839 (Iressa) for Recurrent or Metastatic Squamous Cell Carcinoma of the Skin

Start date: May 2004
Phase: Phase 2
Study type: Interventional

The goal of this clinical research study is to learn if the drug ZD1839 (Iressa) can shrink or slow the growth of cancer in participants with recurrent and/or metastatic squamous cell cancer (SCC) of the skin. The safety of this drug will also be studied.

NCT ID: NCT00054444 Completed - Clinical trials for Cervical Adenocarcinoma

Radiation Therapy and Chemotherapy in Treating Patients With Locally Advanced Cervical Cancer

Start date: September 2007
Phase: Phase 1
Study type: Interventional

This phase I trial is studying the side effects and best way to give radiation therapy when given together with topotecan and cisplatin in treating patients with locally advanced cervical cancer. This trial is also studying the best dose of topotecan when given in this regimen. Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs used in chemotherapy, such as topotecan and cisplatin, use different ways to stop tumor cells from dividing so they stop growing or die. Combining radiation therapy with chemotherapy may kill more tumor cells.

NCT ID: NCT00050388 Completed - Clinical trials for Head and Neck Cancer

Phase II Trial of Allovectin-7® for Head and Neck Cancer

Start date: n/a
Phase: Phase 3
Study type: Interventional

The purpose of this clinical trial is to determine if Allovectin-7®, an experimental gene-based immunotherapy, can shrink head and neck tumors. The trial will also examine if treatment can boost the immune system and if this treatment can improve the time to disease progression.

NCT ID: NCT00049283 Completed - Tongue Cancer Clinical Trials

Erlotinib, Docetaxel, and Radiation Therapy in Treating Patients With Locally Advanced Head and Neck Cancer

Start date: September 2002
Phase: Phase 1
Study type: Interventional

Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Erlotinib may stop the growth of tumor cells by blocking the enzymes necessary for tumor cell growth. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining erlotinib with docetaxel may make the tumor cells more sensitive to radiation therapy and may kill more tumor cells. Phase I trial to study the maximum tolerated dose (MTD) of combining erlotinib with docetaxel and radiation therapy in treating patients who have locally advanced head and neck cancer

NCT ID: NCT00049166 Completed - Clinical trials for Stage III Squamous Cell Carcinoma of the Oropharynx

Erlotinib and Radiation Therapy With or Without Cisplatin in Treating Patients With Mouth or Throat Cancer

Start date: October 2002
Phase: Phase 1
Study type: Interventional

Phase I trial to study the effectiveness of combining erlotinib with radiation therapy with or without cisplatin in treating patients who have advanced mouth or throat cancer. Erlotinib may stop the growth of tumor cells by blocking the enzymes necessary for their growth. Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining erlotinib with radiation therapy with or without cisplatin may kill more tumor cells.

NCT ID: NCT00045526 Completed - Clinical trials for Adenocarcinoma of the Gastroesophageal Junction

Erlotinib Hydrochloride in Treating Patients With Advanced Esophageal Cancer or Stomach Cancer

Start date: June 2002
Phase: Phase 2
Study type: Interventional

This phase II trial is studying erlotinib hydrochloride to see how well it works in treating patients with advanced esophageal cancer or stomach cancer. Erlotinib hydrochloride may stop the growth of cancer by blocking the enzymes necessary for tumor cell growth.

NCT ID: NCT00042926 Completed - Clinical trials for Head and Neck Cancer

Diagnostic Trial in Patients Who Are Undergoing Surgery for Early Stage Mouth Cancer

Start date: May 2002
Phase: N/A
Study type: Interventional

RATIONALE: Diagnostic procedures to detect cancer cells in sentinel lymph nodes may help plan effective cancer treatment. PURPOSE: Diagnostic trial to study the effectiveness of lymph node mapping and sentinel lymph node lymphadenectomy in patients who are undergoing surgery to remove early-stage cancer of the mouth.

NCT ID: NCT00041626 Recruiting - Clinical trials for Carcinoma, Squamous Cell

Effectiveness and Safety of INGN 201 in Combination With Chemotherapy Versus Chemotherapy Alone

Start date: n/a
Phase: Phase 3
Study type: Interventional

There is a need for more treatment options for patients with recurrent squamous cell cancer of the head and neck (SCCHN). These tumors usually have a variety of genetic defects that include disruption of the p53 pathway, a pathway that would ordinarily work to prevent the development of tumors. In this study the transfer of the p53 gene to tumor cells using a modified adenovirus (INGN 201) in combination with chemotherapy (cisplatin and fluorouracil) will be compared to chemotherapy with cisplatin and fluorouracil in patients who have failed surgery and radiotherapy.

NCT ID: NCT00041613 Recruiting - Clinical trials for Carcinoma, Squamous Cell

Study to Compare the Overall Survival of Patients Receiving INGN 201 (Study Drug) With Patients Receiving Methotrexate

Start date: n/a
Phase: Phase 3
Study type: Interventional

There is a need for more treatment options for patients with recurrent squamous cell cancer of the head and neck (SCCHN). These tumors usually have a variety of genetic defects that include disruption of the p53 pathway, a pathway that would ordinarily work to prevent the development of tumors. In this study the transfer of the p53 gene to tumor cells using a modified adenovirus (INGN 201) will be compared to methotrexate in patients who have failed surgery, radiotherapy and chemotherapy with platinum or taxanes.

NCT ID: NCT00041093 Completed - Clinical trials for Recurrent Cervical Carcinoma

Docetaxel in Treating Patients With Persistent or Recurrent Cervical Cancer

Start date: June 2002
Phase: Phase 2
Study type: Interventional

Phase II trial to study the effectiveness of docetaxel in treating patients who have persistent or recurrent cervical cancer. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.